Frog...I'd like to reply to your questions.
YOUR QUESTION: "Why is there no apparent unrest among the faithful concerning the consistent failure of the company to finish anything they ever started?"
MY RESPONSE: The "faithful" tend to have the patience of Thomas Edison and not the typical 3-year old toddler who demands instant success. Edison tested over 10,000 versions of his illuminating bulb before finding a combination that yielded lasting results. I tend to believe genomic research follows the same kind of path. Additionally, start-up research and development firms, high-risk ventures to begin with, are notorious for taking a long time to develop products and/or revenue streams and investors who place money in such risky ventures should be figuring that time into their investment decisions. It seems to me that the question ought not be why haven't they finished anything, but rather, "Are they making progress?" I think DNAprint has demonstrated remarkable progress on the scientific end and I think the "faithful" recognize the value of that progress.
YOUR QUESTION: "How many times does it take to gain some semblance of caution regarding a new promise".
MY RESPONSE: It depends on each individual investor. Some folks sell at the first sign of bad news. Some totally ignore bad news as if it never occurred and others read individual pieces of news as part of a larger picture. Personally, I think there is already more "caution" out there than optimism...otherwise, investorss would be buying DNAP like crazy and the PPS would skyrocket.
YOUR QUESTION: "How many of the faithful are not so much enamored by the future, as trapped by the past?"
MY RESPONSE: Based on DNAprint analysis...22! 8 are of Northern European descent. 5 are hispanic. 2 are Asian. 3 are Native American, one is from Slovenia and three are from sub-saharan Africa. One of the two Asian's has an outstanding parking ticket.
I hope I've answered your questions.
Steve
AI
Market Data 
Markets 
